Tradestie Institutional Equity Comparison Engine

BCAX vs MBX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MBX Overall Edge

MBX Captures Institutional Edge (3โ€“0 Pillars ยท 4โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MBX Biosciences, Inc. Common Stock (MBX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BCAX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MBX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro) against MBX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BCAX N/M vs MBX N/M Fwd P/E
Growth & Margin Winner MBX
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner MBX
1Y -32.8% vs +122.4% ยท 52W Pos 7% vs 62%
Options & Structure Winner MBX
BREAKDOWN (23rd %ile IV) vs UNCLASSIFIED (<1st %ile IV)
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.58
-4.39% 1D
Market Cap $671.2M
1M Return -42.91%
1Y Return -32.82%
Forward P/E N/M
Unified AI Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0
MBX NASDAQ
MBX Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$53.54
-4.29% 1D
Market Cap $2.7B
1M Return +7.92%
1Y Return +122.43%
Forward P/E N/M
Unified AI Score
44.9 / 100 HOLD
Tech 42.0 Fund 47.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BCAX -32.82% MBX +122.43% Spread: +155.25 pp (MBX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BCAX TTM Op. Margin: 0.0% MBX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs MBX. Trailing 12-month operating profitability (BCAX 0.0% vs MBX 0.0%) and valuation multiples (BCAX N/M vs MBX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BCAX (1) vs MBX (4)
Institutional Metric BCAX MBX Criterion Row Winner
Market Capitalization Scale $671.2M $2.7B Larger Scale MBX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -54.2% -33.7% Higher ROE MBX
52-Week Range Position Momentum 7% ($8โ€“$31) 62% ($23โ€“$73) Stronger Trend MBX
Beta / 30D Volatility Risk Regime 1.41ฮฒ ยท 184% Vol 1.58ฮฒ ยท 66% Vol Lower Realized Risk MBX
Unified Institutional Score Composite Signal 52.1 / 100 (HOLD) 44.9 / 100 (HOLD) Higher Composite BCAX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BCAX vs MBX Buy Guide
BCAX BREAKDOWN
93d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live BCAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MBX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live MBX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BCAX nor MBX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.